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OBJECTIVES: To determine recurrent (infective) exacerbations (AECOPD) and
health care utilization among patients with moderate to very severe COPD.
METHODS: Data for this study was obtained from the PHARMO Record Linkage
System (RLS), which includes drug dispensing records from pharmacies, hospital-
ization records and detailed information from general practitioners. Patients with
moderate to very severe COPD (GOLD II-III-IV) and a moderate or severe AECOPD
between 2000 and 2010 were included in the study. Moderate and severe AECOPD
were defined by drug use and hospitalizations respectively. Date of first AECOPD
after first GOLD classification-test was defined as cohort entry. Study patients were
followed from cohort entry to end of registration in PHARMO RLS, death, or end of
study period, whichever occurred first. During follow-up, all recurrent AECOPDs
were counted and characterized by type of AECOPD and health care utilization.
RESULTS:Of 886 patients included in the study, 56% was male and mean (SD) age
was 66 (11) years. The proportion of patients with GOLD II, III and IV was 52%, 34%
and 14% respectively. At cohort entry, 747 patients (84%) had a moderate AECOPD
and 139 (16%) had a severe AECOPD. The overall exacerbation recurrence rate per
person year (PY) was 0.9. When stratifying by GOLD stage at cohort entry, this rate
increased from 0.6 for patients with GOLD II to 1.1 for GOLD III patients and 1.3 for
GOLD IV patients. The rate of severe exacerbations was 0.1 for patients with GOLD
II and III and 0.2 for patients with GOLD IV. Mean hospital stay for severe exacer-
bations was 12 (11) days and 75% were infectious. Moderate exacerbations were
mostly treated with tetracyclines (46%), followed by penicillins (34%).
CONCLUSIONS: This study provides a comprehensive overview of recurrent AE-
COPD among patients with moderate to very severe COPD, but also emphasizes the
need for more research in infective AECOPD.
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OBJECTIVES: To obtain population based data on the prevalence of allergies and to
provide insight into allergy care and perceptions. METHODS: A random represen-
tative sample of the German population (18 years) was recruited for a telephone
survey in 2012. Descriptive data were stratified by criteria relevant for health-
service research as age, sex, geographical region insurance status. RESULTS: For
51% of the n1.004 respondents the topic “allergy” was personally relevant. One
third of all respondents (33%) rated a physician-diagnosed allergy. Prevalence was
higher in women (39%) than in men (27%) and in persons with higher educational
level (39% vs. 33% lowest level). The most common allergen (43%) was pollen; 15%
reported to have contact dermatitis (women 21%, men 5%). The majority of allergic
persons (53%) felt (highly) burdened and 48% were limited in their daily activities
due to symptoms. 70% have ever seen a physician or other therapist for their
allergy (East: 62%, West 72%); GPs (45%) and dermatologists (41%) were consulted
mainly. Self-medication was frequent among allergic persons (58%); it was most
prevalent in the highest income and education groups as well as in West Germany.
Medical treatment of acute symptoms was reported by 21% of the respondents.
Regarding allergy perception, 39% appraised allergies as “easily treatable”; this
opinion was more prevalent in women and in privately insured persons. In an open
question on potential allergy triggers environmental factors were mentioned most
often (26%), chemical agents. CONCLUSIONS: About one-third of the German gen-
eral adult population is affected by allergies and constricted by acute symptoms.
There is evidence for need of improvement concerning awareness and appraisal of
allergies - which are not distributed evenly over social groups. In particular, there is
a gap of using adequate medical treatment of acute symptoms.
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OBJECTIVES: It is estimated that there are 25 million cases of pneumonia world-
wide with 63,500 deaths from the disease annually. Streptococcus pneumoniae
(S.pneumonia) is one of the main pathogens that cause pneumonia. Apart from
S.pneumonia, some other common pathogens include Haemophilus influenzae, Staph-
ylococcus aureus and Klebsiella pneumoniae. However, pneumonia data from South
East Asia is lacking. According to the Department of Statistics Malaysia, pneumo-
nia is one of the top five causes of death in Malaysia. This study sought to describe
pneumonia mortality in Malaysia using death statistics from the Department of
Statistics Malaysia. METHODS: This study used death data from 2004 to 2008 ob-
tained from Department of Statistics Malaysia. For the purpose of analysis, medi-
cally certified deaths that were due to pneumonia were analysed by age group.
Pneumonia death rate was calculated against the population age cohorts for each
year. Rates were reported in deaths per 100,000 population. RESULTS: The average
crude mortality rate in Malaysia for the period 2004 to 2008 ranged from 440.4 to
454.0 per 100,000 population. However, deaths attributed to pneumonia showed an
increasing trend from 11.9 (2004), 12.9 (2005), 13.8 (2006), 15.6 (2007) and 19.3 (2008)
per 100,000 population. CONCLUSIONS: Deaths due to pneumonia over the period
2004 to 2008 have shown an increase even though the crude death rate has been
stable during that time. Further analysis to determine pathogens and aetiology of
the pneumonia deaths is warranted.
RESPIRATORY-RELATED DISORDERS - Cost Studies
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OBJECTIVES: To estimated the budget impacts of immunization against pneumo-
coccal disease (PD) and human papillomavirus (HPV), and of prophylaxis against
severe respiratory syncytial virus (RSV) disease, in Israel. METHODS: Incidence-
based models compared the annual budget impact, from the Israeli health care
system perspective, of the PD and RSV programs. Because HPV disease is slow
developing, cumulative five-year disease costs were instead modelled for this pro-
gram. Model inputs were from published literature. Outputs included total pro-
gram cost, disease costs and disease cost offsets, in 2012 Israeli New Shekels (NIS).
RESULTS: A 13-valent pneumococcal conjugate vaccine (PCV13) vaccination pro-
gram, covering 175,428 infants, prevented approximately 78 cases of invasive dis-
ease, 218 of pneumococcal pneumonia and 225 of pneumococcal otitis media. Im-
munization against HPV in a year’s cohort of 66,185 twelve-year old girls prevented
approximately 321 cases of cervical intraepithelial neoplasia and 48 cases of genital
warts over five years. RSV prophylaxis in 2,266 high-risk infants prevented approx-
imately 138 hospitalizations for severe RSV disease. Total disease costs in year one
of the model, without the programs, were 7,250,461 NIS (PD) and 17,988,932 (RSV
infection); cumulative five-year disease costs in the HPV model without immuni-
zation were 1,331,194 NIS. Total disease costs, with the programs (excluding the
cost of prophylaxis) were 3,305,522 NIS (PD) and 14,426,876 NIS (RSV disease), for
annual savings of 3,944,939 NIS and 3,562,056 NIS, respectively. HPV disease costs
over five years with the program were 535,480 NIS, saving an estimated 795,713 NIS
over five years. The immunization programs cost: 133,135,790 NIS (PD), 35,106,399
NIS (HPV) and 34,888,624 NIS (RSV disease). CONCLUSIONS: All programs had sub-
stantial acquisition costs, but annual net savings, when the costs of the program
were excluded. Even programs considered expensive are well-positioned finan-
cially within the context of other childhood preventive health strategies, when
targeted to appropriate populations.
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OBJECTIVES:A significant economic burden for society is linked to chronic obstruc-
tive lung diseases because of their high and still growing epidemiologic impact
worldwide. The purpose of this systematic review is to estimate the cost-of-illness
per case for the two most important obstructive lung diseases, asthma and COPD,
for adults in Germany.METHODS:A systematic search of Pubmed, Embase, EconLit
and Business Source Complete was performed for the years 1995 to 2012 in order to
identify German cost-of-illness studies for asthma and COPD. Studies identified
were analysed according to methods used, and cost findings were inflated to 2010
prices and compared within the same disease. RESULTS: Six studies for asthma,
seven for COPD and one for both diseases met the inclusion criteria. The costs for
asthma differ widely, ranging from minimum to maximum by a factor of 6.7 for
direct costs and 9.6 for indirect costs per case. For COPD, costs per case ranged by a
factor of 4.2 for direct costs and of 6.5 for indirect costs. In spite of the heterogeneity
in methodology and results, medication could be identified as the most important
single component of direct costs, and work loss as the most important component
of indirect costs. All in all, the estimated costs per case of illness and year varied by
a factor of 5.7 with a maximum slightly above 2,500 € for asthma and by a factor of
2.9 with a maximum of almost 3,500 € for COPD. CONCLUSIONS: Findings confirm
that asthma and COPD are costly but results vary markedly. COPD causes both
higher costs per case and higher total costs as a result of its higher prevalence.
Results emphasize the economic relevance of effective prevention and disease
management for these chronic obstructive lung diseases.
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OBJECTIVES: To evaluate direct costs of allergen immunotherapy with regard to its
clinical benefit in the treatment of allergic rhinitis in the Slovak Republic.
METHODS: In co-operation with the General Health Insurance Company, the larg-
est insurer in Slovakia covering approximately 66% of all patients, the clinical
benefits were analyzed with respect to direct medical costs (cost of illness), costs
minimization and prevention of onset of asthma bronchiale (AB), in a short- and a
long-term period. The outcomes were obtained from an analysis of a group of
109,974 patients who were newly diagnosed with allergic rhinitis (AR) in 2002 and
were followed up until the end of 2010. In 2010, allergic rhinitis was detected in only
14,742 of these patients. RESULTS: The prevalence of AR and AB was 9.34% and
4.74%, respectively. In 2010, the total direct costs of AR and AB in Slovakia were
approx. 37,946,000 € and 51,512,000 €, respectively. Direct medical costs of AR and
AB treatment in 2010 in the evaluated group were 50.14 € and 198.03 €, respectively.
Allergen immunotherapy decreases average annual costs of pharmacotherapy of
AR by 17 € per patient and annual costs of prevention of onset of AB by 164.89 € per
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patient. Compared to symptomatic therapy, patient with AR treated with allergen
immunotherapy obtained approx. 0.75 month (3 years of vaccination followed by
5-year evaluation) and 3.45 month (4-year follow up including 3 years of vaccina-
tion) without AB. The QALY for costs has been calculated between 8516 € - 8883 €.
CONCLUSIONS: In the Slovak Republic, Staloral allergen immunotherapy of aller-
gic rhinitis is effective from the clinical as well as pharmacoeconomic point of
view.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) poses a significant
burden on health care budgets. The impact of impaired and lost productivity is less
known. The aim of this study was to explore the economic burden of COPD in
patients of working age in The Netherlands across three areas: health care utiliza-
tion, impaired productivity and lost productivity resulting from early retirement
due to COPD. METHODS: Dutch direct medical costs were derived from a literature
review and applied to individual COPD patients. Costs of productivity impairment
due to COPD were estimated from the ‘COPD uncovered’ survey, adopted for The
Netherlands. Costs due to lost productivity due to early retirement were based on
a cohort of COPD patients of working age followed in a Markov model for 20 years
until (early) retirement or death. The costing year was 2011. RESULTS: The annual
health care costs for patients with COPD aged 45-64 years in The Netherlands were
estimated at around €70 million. The annual impaired productivity costs were €120
million. Lost productivity due to early retirement were estimated at around €510
million per year; the majority of €350 million for men and €160 million for women.
These lost productivity costs represented 21% of the productivity that may have
been generated by COPD patients if they had not retired early. CONCLUSIONS: The
‘COPD UNCOVERED’ model was used to estimate the economic burden of COPD in
The Netherlands. Costs due to impaired and lost productivity in COPD patients of
working age was considerable and several times higher than the medical cost of
COPD. Young working population provide a main target for interventions aimed to
improve COPD disease management.
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OBJECTIVES: According to the GOLD report (2011), COPD is associated with signif-
icant economic burden. For Ukraine as for developing country, the human capital
(employed economically active population) is the most important national asset
and COPD-related work-place loss may represent a serious threat for Ukrainian
economics. METHODS: Via the best fit (least square) linear regression forecast we
modeled the 2012-2020 dynamics of the key socioeconomic and COPD-related ep-
idemiological indicators for general Ukrainian population and employed econom-
ically active population. Modeling was based on the 2005-2011 reports of the Ukrai-
nian National Center of Statistics and data from WHO. Using forecasting results the
number of new COPD cases and COPD-related deaths 2012-2020 was calculated.
Also we calculated and compared 2012 and 2020 direct and indirect costs.
RESULTS: According to the forecasting results, number of total Ukrainian popula-
tion and employed economically active population could amount 45453100 and
20393267, respectively, in 2012 and 43484907 and 20845448, respectively, in 2020.
Number of COPD patients in 2012 and 2020 could be 1766748 and 1731332, respec-
tively, in general population and 792680 and 829952, respectively, in employed
economically active population. Number of 2012-2020 new COPD cases and COPD
related deaths could be 1230750 and 56207, respectively, in general population and
570737 and 25892, respectively, in employed economically active population. We
estimated that in 2012 direct COPD costs could be 87,17% greater than indirect
COPD costs and could amount to €326367598 vs. €193607579,9, respectively. In 2020
indirect COPD costs could 1,47% exceed the direct costs and could amount
€496997427,8 vs. 489796409, respectively. CONCLUSIONS: Results of modeling
show that socioeconomic burden of COPD will be significant for Ukraine during the
2012-2020 periods. COPD costs will rise with the significant growth of indirect costs,
which may be typically for Ukraine as for developing country.
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OBJECTIVES: Asthma, a major chronic respiratory disease, has become a cause of
global concern in terms of its increasing prevalence, morbidity and economic im-
pact.Our aim was to examine the availability, pricing and affordability of asthma
medicines in Tehran. METHODS: The study methodology was designed using the
recommendations developed by the World Health Organization and Health Action
International on measuring medicine prices, availability, affordability and price
components. Data was collected from 5 public sector facilities and 10 private sector
retail pharmacies in the pilot study in 22 regions of Tehran.Data on price of inno-
vator brands (IBs) and lowest priced generics (LPGs) found at each facility were
gathered and applied for data analtysis. RESULTS: Generic beclomethasone was
found in 3 public sectors and generic salbutamol was available in 4 public sec-
tors.The availability of IB beclomethasone was poor in all of the regions surveyed
.IB beclomethasone was available at 2 out of 5 and 5 out of 10 pharmacies surveyed
in public and private sectors, respectively. The availability of generic beclometha-
sone inhalers was 90%. IB salbutamol inhalers were available in all the surveyed
regions.At the time of the survey, the lowest paid unskilled government worker
earned 108 400 Iranian Rials (IRR) (US$ 11.78) per day. CONCLUSIONS: The poor
availability of inhalers at public facilities affects those patients who depend on
these facilities for treatment and medications. In the past decade, some barriers
were imposed by the Ministry of Health on registering certain pharmaceuticals . A
new approach has focused on reducing these barriers and there is a need for stron-
ger government action to introduce or improve national medicine policy as well as
effective pricing policies.
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OBJECTIVES: To systematically identify economic evaluations of treatments rec-
ommended for chronic idiopathic urticaria (CIU) and studies reporting health-state
utility weights and/or estimates of resource use and costs. METHODS: Systematic
searches of MEDLINE, MEDLINE-In-Process, EconLit, EMBASE, the Cochrane Li-
brary, and conference abstracts were conducted from 1 January 2000 to 20 Decem-
ber 2011. Inclusion criteria considered studies reporting utility weights, resource
use, costs, and/or economic evaluations of treatments in CIU patients older than 12
years. RESULTS: From 266 retrieved records, 3 studies were included: 1 economic
evaluation of levocetirizine and 2 cost studies. The economic evaluation was a
pooled analysis of two clinical trials comparing levocetirizine with placebo and
incorporating productivity losses defined as absenteeism and/or presenteeism.
One cost study reported total annual per-patient direct costs of $1,762; the other
study reported a cost range between $1,290 and $2,419, depending on disease se-
verity. Cost components included prescriptions, visits, hospitalisations, and labo-
ratory costs. Annual per-patient indirect costs, defined as disease-related loss of
earnings, were between $213 and $484, depending on severity. Although no utility
studies in CIU were found, one study demonstrated that CIU severely impairs
health-related quality of life at the same level as skin conditions, such as psoriasis
and atopic dermatitis, on certain dimensions. CONCLUSIONS: This review identi-
fied limited evidence on costs, only one economic evaluation, and no utility data for
CIU. Lacking comparative data, it is impossible to conclude what the most cost-
effective treatment in CIU might be. Due to discrepancies between the cost studies,
it is difficult to conclude which cost component contributed the most; however,
one study reported that productivity loss was a major component. This review
highlighted the substantial cost burden and a humanistic burden, comparable to
other skin disorders, of CIU. Further research in this area is needed.
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OBJECTIVES: According to the GOLD report (2011) COPD is associated with signifi-
cant economic burden. COPD exacerbations account for the greatest proportion of
the total COPD costs. Frequency and severity of COPD exacerbation could be re-
duced by the appropriate medication that could be reimbursed by Ukrainian
Government.METHODS:To determine the net benefit ratio we assessed total COPD
costs and the COPD exacerbation-related costs reduction as benefit (effectiveness)
for tiotropium (18 mcg daily) and salmeterol (50 mcg two times a day) compared to
usual COPD treatment practice of GPs. Direct costs included medication costs,
outpatient and inpatient costs. Indirect costs included productivity loss and tem-
porary disability related payments. Calculations were performed per 1000 em-
ployed economically active COPD patients. The data about the outpatient visits and
hospitalizations was received from results of Ukrainian retrospective study (for
usual practice regimen) and from the POET study results (for tiotropium and sal-
meterol). Prices for medical services were received from appropriate survey (2011)
and were counted with May 2011-May 2012 inflation index and salary growth rates.
The minimal market medication prices (on 15 June 2012) were included in calcula-
tions. Sensitivity analysis was conducted with medication price decrease.
RESULTS: Results show that total COPD costs per 1000 employed economically
active COPD patients in 2012 could amount €498052,34, €441697,07 and €508983,73
with usual COPD treatment practice of GPs, salmeterol and tiotropium, respec-
tively. Reduction of exacerbation-related COPD costs compared to usual practice
could amount €85698,78 for salmeterol and €114380,78 for tiotropium. Cost benefit
ratio for salmeterol could be 5,15 and for tiotropium could be 4,45. In case of 27%
price drop salmeterol could be more beneficial than tiotropium. CONCLUSIONS:
According to results of the cost-benefit analysis tiotropium is more beneficial for
COPD basis in employed economically active Ukrainian population than salmeterol
compared to usual practice. It could be reimbursed by Ukrainian government.
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